Advertisement

Topics

The Medicines Company PCSK9 Inhibitor Strategy -- More Heart Patients Via Lower Pricing

02:35 EST 9 Nov 2017 | Forbes

Meanwell believes that inclisiran can be a very successful drug at a much lower price than Repatha and Praluent.

Original Article: The Medicines Company PCSK9 Inhibitor Strategy -- More Heart Patients Via Lower Pricing

NEXT ARTICLE

More From BioPortfolio on "The Medicines Company PCSK9 Inhibitor Strategy -- More Heart Patients Via Lower Pricing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...